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plus best supportive care (OT+ BSC) versus best supportive care (BSC) 
alone using the EQ-5D assessment in a clinical trial in SCLC. Informa-
tion from ongoing studies supports that a minimal important difference 
(MID) in lung cancer of 0.08 can be used to further interpret results 
obtained for EQ-5D Index.
Methods: Data were analyzed from a randomized, open-label, mul-
ticenter trial in 141 SCLC patients receiving either OT+BSC or BSC 
alone where health status was assessed by patient self-report using the 
EQ-5D Index and the EQ-5D Visual Analogue Scale (VAS). EQ-5D is 
a questionnaire that covers multi-attribute health outcomes, including 
mobility, self-care, usual activity, pain/discomfort, and anxiety/depres-
sion, as an overall measurement of patient health status. The Index 
is scored on a scale from 0 (dead) to 1 (perfect health), and the VAS 
scores range from 0 (worst health) to 100 (best health). The EQ-5D 
measures were administered at baseline and at 3-week intervals at 
subsequent four visits. Change from baseline in EQ-5D Index and EQ-
5D-VAS was assessed using a pooled analysis (change from baseline to 
averaged on-treatment assessments) and also considering only change 
from baseline to last evaluation. Rate of change in EQ-5D Index scores 
(rate at which symptoms improved or deteriorated) across treatment 
groups was analyzed using a mixed model to account for repeated 
measurements over the treatment course. 
Results: A signiﬁcantly smaller decline in EQ-5D Index and VAS 
change scores were observed for the OT+BSC than BSC groups in both 
pooled and last evaluation analyses (Table). The rate of change from 
baseline per 3-month interval for EQ-5D Index score was -0.05 (95% 
CI: -0.11, 0.02) for OT+BSC and -.20 (95% CI, -0.27, -0.12) for BSC, 
indicating a decline for both groups, but a signiﬁcantly slower decline 
for OT+BSC.
Table: Change in EQ-5D Scores from Baseline to Treatment Periods
 Baseline Treatment Change from baseline   
 Mean Mean Mean Diﬀerence  (OT+BSC vs. BSC) p value
Pooled Analysis 
EQ-5D Index 
OT+BSC (n=239) 0.72 0.69 -0.03   
BSC (n=167) 0.68 0.56 -0.12 0.09 0.0036
EQ-5D VAS 
OT+BSC (n=238) 66.46 66.76 0.30   
BSC (n=162) 67.22 59.80 -7.41 7.71 <0.0001
Change from Baseline to Last Evaluation Analysis 
EQ-5D Index 
OT+BSC (n=61) 0.70 0.61 -0.10   
BSC (n=51) 0.65 0.34 -0.30 0.2 0.0034
EQ-5D VAS 
OT+BSC (n=60) 65.75 61.77 -3.98   
BSC (n=48) 64.29 49.83 -14.46 10.48 0.0025
 
Conclusion: Results for the EQ-5D Index indicate a smaller and slower 
decline in health status from baseline for OT+BSC compared to BSC. 
The between groups difference in magnitude of decline exceeded the 
established MID. In addition, results for EQ-5D VAS also showed a 
smaller decline for OT+BSC.
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Background: Small cell lung cancer (SCLC) makes up 15-20% of 
all lung cancer cases worldwide. SCLC is a very aggressive form of 
cancer and is characterised by early metastasis. As a result, chemo-
therapy is the mainstay of treatment in SCLC. A number of different 
platinum based and non-platinum based chemotherapy regimes have 
been trialled for the treatment of SCLC, with varying results. The aim 
of this project was to analyse the data from these trials in a Cochrane 
systematic review (SR) comparing platinum vs. non-platinum base che-
motherapy regimes in SCLC with regards to survival, tumour response, 
toxicity and quality of life (QOL).
Methods: A search of biomedical literature databases (MEDLINE, 
EMBASE, CINAHL, CENTRAL) was conducted in order to identify 
all randomised controlled trials that involved patients with histologi-
cally conﬁrmed SCLC and the use of platinum based chemotherapy 
regimes. Information about included trials was recorded in order to 
assess for methodological quality. The following results from the 
included trials were also recorded: Survival (at 6 months, 12 months 
and 24 months), tumour response (objective overall response (OOR)), 
complete response (CR)), toxicity and QOL. The results of the survival, 
tumour response and toxicity data were combined in a meta-analysis.
Results: A total of 29 trials involving 5530 patients were included in 
this SR. In terms of 6 month survival, there was a statistically signiﬁ-
cant difference favouring platinum based chemotherapy regimes (Odds 
ratio (OR) 1.19; 95% CI: 1.06-1.35). Platinum based chemotherapy 
regimes were also favoured in terms of 12 month and 24 month sur-
vival, however, for these time periods, the difference was not statisti-
cally signiﬁcant. OR for twelve month survival was 1.08 (0.97-1.22) 
and 24 month survival was 1.05 (0.87-1.26). There was a statistically 
signiﬁcant difference favouring platinum based chemotherapy regimes 
in terms of OOR and CR. The OR for OOR was 1.26 (1.12-1.41) and 
for CR was 1.39 (1.21-1.59). Platinum based chemotherapy regimes 
had signiﬁcantly higher rates of nausea and vomiting (OR 1.58; 1.28-
1.94), anaemia (OR 1.72; 1.26-2.35) and thrombocytopaenia (OR 3.44; 
2.68-4.41) toxicity. Non-platinum based chemotherapy regimes had a 
signiﬁcantly higher rate of leukopaenia toxicity (OR 0.75; 0.62-0.91). 
There was no signiﬁcant difference in the rate of toxic death (OR 1.09; 
0.77-1.54). Only 3 trials presented QOL data and the data presented by 
these trials was not able to be combined in a meta-analysis.
Conclusion: Despite platinum based chemotherapy regimes invoking 
a signiﬁcantly higher tumour response, both in terms of OOR and CR, 
these regimes did not offer a signiﬁcant long-term survival beneﬁt over 
non-platinum based chemotherapy regimes. Platinum based chemo-
therapy regimes were associated with higher rates of toxicity, except 
for leukopaenia toxicity. This SR also highlighted the lack of QOL data 
in trials involving chemotherapy treatment for SCLC. With poor long-
term survival associated with both treatment groups, the issue of the 
QOL of the survival period takes on even more signiﬁcance. It would 
be beneﬁcial for future trials into this area to include a QOL assess-
ment.
